Skip to main content
NVDA-0.93%AAPL+1.69%GOOGL-11.92%MSFT-1.23%AMZN-3.10%TSM-1.35%SPCX-0.83%AVGO-2.77%TSLA+0.28%META+1.99%LLY+7.27%SKHY-0.78%BRK-B+0.77%MU-3.01%WMT+1.12%AMD-1.66%JPM+1.77%XOM+0.74%V+2.61%JNJ+1.46%ASMLa+0.48%MA+4.70%ABBV+1.58%INTC-2.62%1398.HK+2.23%CVX+0.75%0700.HK-2.58%ORCL-2.95%COST+0.25%CSCO-0.55%KO+0.69%1816.HK+7.22%PG+0.29%UNH+0.52%BAC+1.94%3988.HK+1.66%AMAT+0.45%CAT-7.44%AP2d+0.94%0857.HK+2.91%LRCX+1.07%HD+1.87%PM+1.31%DELL-0.85%0939.HK+2.12%GE+3.35%1288.HK+1.48%MS+1.03%0005.HK-0.07%HSBA.L+0.12%NZDCAD-1.53%NZDUSD-1.42%AUDNZD+1.31%GBPNZD+1.21%NZDCHF-1.12%EURNZD+0.98%USDMXN+0.79%NZDJPY-0.79%CADJPY+0.77%NZDMXN+0.67%USDJPY+0.65%EURCAD-0.53%AUDJPY+0.53%EURSEK-0.45%USDSEK-0.44%EURUSD-0.44%GBPTRY+0.41%AUDSGD-0.41%CADCHF+0.41%GBPJPY+0.40%AUDDKK-0.39%CHFSEK-0.38%GBPCAD-0.36%CHFJPY+0.36%GBPHKD+0.32%EURAUD-0.31%USDCHF+0.30%GBPMXN-0.28%AUDNOK-0.28%USDTRY+0.28%GBPUSD-0.24%GBPZAR+0.24%AUDCAD-0.23%EURJPY+0.22%PLNJPY+0.20%EURGBP-0.19%AUDCHF+0.19%USDPLN-0.18%EURPLN-0.18%CHFNOK+0.18%USDILS+0.16%USDTHB-0.15%EURCHF-0.15%USDZAR+0.14%NZDSGD-0.13%USDCNH-0.13%EURZAR+0.13%AUDUSD-0.12%GBPAUD-0.12%EURNOK+0.11%USDNOK+0.11%USDCAD-0.09%NOKJPY-0.09%GBPSGD+0.07%EURCZK-0.07%USDHKD+0.06%SGDJPY+0.05%GBPCHF+0.05%EURCNH-0.05%USDCOP-0.04%CHFSGD+0.04%EURSGD-0.03%USDSGD-0.03%EURHKD+0.01%USDDKK0.00%EURDKK0.00%XPTUSD-4.13%GAGUSD-2.95%XAGUSD-2.95%HG1-1.70%XNGUSD-1.53%USOIL-1.17%XAUUSD-1.06%GAUUSD-1.06%SUGAR+0.62%COTTON+0.51%COCOA-0.44%UKOIL-0.42%BTCUSD-1.07%ETHUSD+22.03%USDTUSD-0.03%XRPUSD+13.23%SOLUSD+15.69%TRXUSDT+0.65%ZECUSDT-2.76%DOGEUSD+17.55%XMRUSDT+0.31%LINKUSD+21.12%BCHUSDT-3.23%XLMUSD-0.93%UNIUSD-0.71%LTCUSD+13.00%SUIUSD-1.02%HBARUSDT-1.13%TONUSD+38.24%TAOUSDT-1.62%AAVEUSD-0.50%DOTUSDT-1.47%ICPUSDT-2.45%ONDOUSDT-1.23%WLDUSDT+1.93%ARBUSDT-1.13%JUPUSDT-3.37%INJUSDT+5.97%ATOMUSDT-1.80%STXUSDT-1.97%TIAUSDT-2.37%PYTHUSDT-0.31%FETUSDT-1.66%SEIUSDT-4.03%IMXUSDT-2.50%GRTUSDT-2.09%OPUSDT-1.41%WIFUSDT-2.27%IOTAUSDT+1.13%POLUSDT-0.28%AXSUSDT-2.58%EOSUSDT+1.48%FARTCOINUSDT+1.48%DYDXUSDT+1.77%GALAUSDT-2.34%ORDIUSDT+1.72%RONINUSDT+2.29%NOTUSDT+2.25%NVDA-0.93%AAPL+1.69%GOOGL-11.92%MSFT-1.23%AMZN-3.10%TSM-1.35%SPCX-0.83%AVGO-2.77%TSLA+0.28%META+1.99%LLY+7.27%SKHY-0.78%BRK-B+0.77%MU-3.01%WMT+1.12%AMD-1.66%JPM+1.77%XOM+0.74%V+2.61%JNJ+1.46%ASMLa+0.48%MA+4.70%ABBV+1.58%INTC-2.62%1398.HK+2.23%CVX+0.75%0700.HK-2.58%ORCL-2.95%COST+0.25%CSCO-0.55%KO+0.69%1816.HK+7.22%PG+0.29%UNH+0.52%BAC+1.94%3988.HK+1.66%AMAT+0.45%CAT-7.44%AP2d+0.94%0857.HK+2.91%LRCX+1.07%HD+1.87%PM+1.31%DELL-0.85%0939.HK+2.12%GE+3.35%1288.HK+1.48%MS+1.03%0005.HK-0.07%HSBA.L+0.12%NZDCAD-1.53%NZDUSD-1.42%AUDNZD+1.31%GBPNZD+1.21%NZDCHF-1.12%EURNZD+0.98%USDMXN+0.79%NZDJPY-0.79%CADJPY+0.77%NZDMXN+0.67%USDJPY+0.65%EURCAD-0.53%AUDJPY+0.53%EURSEK-0.45%USDSEK-0.44%EURUSD-0.44%GBPTRY+0.41%AUDSGD-0.41%CADCHF+0.41%GBPJPY+0.40%AUDDKK-0.39%CHFSEK-0.38%GBPCAD-0.36%CHFJPY+0.36%GBPHKD+0.32%EURAUD-0.31%USDCHF+0.30%GBPMXN-0.28%AUDNOK-0.28%USDTRY+0.28%GBPUSD-0.24%GBPZAR+0.24%AUDCAD-0.23%EURJPY+0.22%PLNJPY+0.20%EURGBP-0.19%AUDCHF+0.19%USDPLN-0.18%EURPLN-0.18%CHFNOK+0.18%USDILS+0.16%USDTHB-0.15%EURCHF-0.15%USDZAR+0.14%NZDSGD-0.13%USDCNH-0.13%EURZAR+0.13%AUDUSD-0.12%GBPAUD-0.12%EURNOK+0.11%USDNOK+0.11%USDCAD-0.09%NOKJPY-0.09%GBPSGD+0.07%EURCZK-0.07%USDHKD+0.06%SGDJPY+0.05%GBPCHF+0.05%EURCNH-0.05%USDCOP-0.04%CHFSGD+0.04%EURSGD-0.03%USDSGD-0.03%EURHKD+0.01%USDDKK0.00%EURDKK0.00%XPTUSD-4.13%GAGUSD-2.95%XAGUSD-2.95%HG1-1.70%XNGUSD-1.53%USOIL-1.17%XAUUSD-1.06%GAUUSD-1.06%SUGAR+0.62%COTTON+0.51%COCOA-0.44%UKOIL-0.42%BTCUSD-1.07%ETHUSD+22.03%USDTUSD-0.03%XRPUSD+13.23%SOLUSD+15.69%TRXUSDT+0.65%ZECUSDT-2.76%DOGEUSD+17.55%XMRUSDT+0.31%LINKUSD+21.12%BCHUSDT-3.23%XLMUSD-0.93%UNIUSD-0.71%LTCUSD+13.00%SUIUSD-1.02%HBARUSDT-1.13%TONUSD+38.24%TAOUSDT-1.62%AAVEUSD-0.50%DOTUSDT-1.47%ICPUSDT-2.45%ONDOUSDT-1.23%WLDUSDT+1.93%ARBUSDT-1.13%JUPUSDT-3.37%INJUSDT+5.97%ATOMUSDT-1.80%STXUSDT-1.97%TIAUSDT-2.37%PYTHUSDT-0.31%FETUSDT-1.66%SEIUSDT-4.03%IMXUSDT-2.50%GRTUSDT-2.09%OPUSDT-1.41%WIFUSDT-2.27%IOTAUSDT+1.13%POLUSDT-0.28%AXSUSDT-2.58%EOSUSDT+1.48%FARTCOINUSDT+1.48%DYDXUSDT+1.77%GALAUSDT-2.34%ORDIUSDT+1.72%RONINUSDT+2.29%NOTUSDT+2.25%
UP

UroGen Pharma Ltd. (URGN)

NASDAQ • Healthcare

$33.75
-$0.15 (-0.5%)
Market open

Last close at October 28, 2026 at 20:00 UTC

Open$33.66
Previous Close$33.75
Day Range$33.1 - $34.04
Avg. Volume (3M)1M
Market Cap$1.6B
52 Week Range
$16.5$50.81
Next EarningsIn 6 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$72.4M100%
Gross Profitminus cost of goods$65.8M91%
Operating Incomeminus R&D and overhead$111K0%

In plain terms: out of every $100 in revenue, UroGen Pharma Ltd. currently loses $20.

Fundamentals & Financials

Revenue (TTM)
$188.7M
Net Income (TTM)
-$97.6M
EPS (TTM)
-$1.98
ROA (TTM)
-38.65%
Current Ratio
3.8

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-4.2%Q1 2026-$0.54
+16.1%Q2 2026-$0.47
-5.7%Q3 2026-$0.28
Next

Nov 4

in 6 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -5.7%

UroGen Pharma’s revenue topped consensus but EPS trailed expectations in the second fiscal quarter of 2026, reported August 5, 2026, as sales growth outpaced the bottom-line improvement. Revenue rose 199.2% to about $72.5 million (up from about $24.2 million a year ago) and topped the $63.5 million estimate (+14%), while EPS of -$0.28 trailed the -$0.27 estimate (difference -$0.02) but improved from -$1.05 a year ago. Profitability was reflected in gross profit of roughly $65.9 million alongside gross margin of ~91%, and net income narrowed to a loss of about $14.4 million (from a loss of roughly $49.9 million a year ago), a +71.3% year-over-year change. Cash generation remained negative, with negative operating cash flow of about $33.0 million. For the next period, consensus calls for EPS of $0.10 on revenue of $90.6 million.

Next report — what to expect

UroGen Pharma Ltd. is scheduled to report earnings on November 5, 2026. With limited recent consistency, the company has beaten EPS in 3 of its 8 most recent quarters, so traders may focus on whether results align with that mixed beat/miss pattern and any updates provided alongside the release.

View full earnings history

About UroGen Pharma Ltd.

UroGen Pharma Ltd. develops and commercializes treatments for urothelial and specialty cancers. Listed on NASDAQ as URGN, it operates as a biotechnology company built around localized drug delivery and cancer therapeutics, and it generated $109.8 million of revenue in FY2025.

Name
UroGen Pharma Ltd.
CEO
Elizabeth Barrett
Website
www.urogen.com
Industry
Healthcare
Year Founded
2004
Employees
300

Today's Snapshot

AI-generated

Yesterday URGN finished slightly down at 33.75. Oppenheimer, an investment bank, reiterated its Outperform rating and $60 target for UroGen Pharma.

Trading Volume

Above 10d avg 921.2K

1.5M

vs S&P 500 Today

Underperforming Market

-0.75%

Updated: October 29, 2026 at 12:21 UTC

Technical Indicators

3 Buy0 Neutral5 Sell
URGN shows a sell bias driven by a strong downward trend and weak volume: ADX above 35 signals a robust trend to the downside while OBV is weakening. Momentum readings are mixed—RSI and Stochastic are in oversold territory suggesting short-term exhaustion, yet MACD and CCI remain negative. The share price sits below most short- and medium-term averages but remains above the 200-day level, indicating shorter-term weakness against longer-term support. Volatility is elevated with ATR around 1.8 and the pivot is close to the current price. Technical takeaway: Sell — strong downtrend with short-term oversold readings.
All signals
  • EMA (5 indicators)$32.31 - $39.00
    Sell
  • RSI (14)29.49
    Buy
  • Stochastic %K (14, 3, 3)8.67
    Buy
  • MACD Level (12, 26)-2.09
    Sell

Peers & Related Assets

CGONCG Oncology Inc.
$63.96+1.6%
RLMDRelmada Therapeutics, Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.